US Edition
Abbott Diabetes head talks Medtronic deal, exciting times ahead
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Abbott Diabetes head talks Medtronic deal, exciting times ahead
EVP, Diabetes Care, Chris Scoggins. [Image courtesy of Abbott]For many, a partnership between Abbott (NYSE:ABT) and Medtronic (NYSE:MDT), two medtech giants and frequent competitors, would have seemed unlikely. The two companies battle for market share in a variety of spaces, including cardiac implants, vascular access, neuromodulation and more. They’ll continue to duke it out in those areas, but in diabetes, they’ve become collaborators. Last s…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
